AIP
CYCN icon

Ameritas Investment Partners’s Cyclerion Therapeutics CYCN Stock Holding History

Ameritas Investment Partners’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-102
Closed -$6K – 3096
2021
Q1 		$6K Hold
102
– – ﹤0.01% 2975
2020
Q4 		$6K Hold
102
– – ﹤0.01% 2935
2020
Q3 		$12K Hold
102
– – ﹤0.01% 2625
2020
Q2 		$12K Hold
102
– – ﹤0.01% 2620
2020
Q1 		$5K Hold
102
– – ﹤0.01% 2806
2019
Q4 		$6K Hold
102
– – ﹤0.01% 2870
2019
Q3 		$25K Hold
102
– – ﹤0.01% 2268
2019
Q2 		$23K Buy
+102
New +$28.9K ﹤0.01% 2363

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameritas Investment Partners's CYCN Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Cyclerion Therapeutics (CYCN) in Q2 2021, closing a stake of 102 shares — an estimated $6K sold.

Ameritas Investment Partners first reported a position in CYCN in Q2 2019 and held it in 8 quarters. The position peaked at $25K in Q3 2019. 67 funds tracked by Wall St. Rank hold CYCN as of Q2 2021.

  • Ameritas Investment Partners reported no remaining Cyclerion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 102 Cyclerion Therapeutics shares in Q2 2021, an estimated $6K.
  • Ameritas Investment Partners first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 8 quarters.
  • Ameritas Investment Partners's Cyclerion Therapeutics position peaked at $25K in Q3 2019.
  • 67 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.